Clinical Impact of the M184V Mutation on Switching to Didanosine or Maintaining Lamivudine Treatment in Nucleoside Reverse?Transcriptase Inhibitor–Experienced Patients
Open Access
- 15 August 2003
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 188 (4) , 537-540
- https://doi.org/10.1086/377742
Abstract
Virologic outcome among 104 lamivudine (3TC)–experienced individuals infected with human immunodeficiency virus type 1 who switched to a didanosine (ddI)–containing triple- or quadruple-drug regimen was compared with those who continued receiving a 3TC-containing regimen. A significantly increased independent risk of virologic failure was associated with continuing a 3TC-containing regimen. In addition, most patients for whom the ddI-containing regimen failed lost the M184V/I mutation. These results show that ddI continues to provide activity against viruses with the M184V/I mutation and suggest that the presence of the M184V/I mutation should not preclude the use of ddI in nucleoside-experienced patientsKeywords
This publication has 0 references indexed in Scilit: